This preview shows page 1. Sign up to view the full content.
Unformatted text preview: Study leader Professor John Neoptolemos, director of the Liverpool Cancer Research UK Centre based at the University of Liverpool, said: Importantly this means patients now have a backup in case their cancer fails to respond to the first line of treatment. A new trial investigating whether combining these two treatments could be even more effective and prolong life is already under way and we look forward to seeing the result. The trial, ESPAC-3 (European Study Group for Pancreatic Cancer) recruited more than 1,000 patients at 159 centres in Europe, Australasia, Japan and Canada. One group of patients received the standard treatment, gemcitabine, while another was prescribed 5-FU. The results mean that 5-FU should now also be considered one of the standard options for the treatment of pancreatic cancer....
View Full Document
- Spring '10